SLDB Live signals | Maximize Profits with Getagraph.com

SELL 158016 min ago

@ $8.00

Issued: 14 Feb 2024 @ 09:30

Return: 3.25%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 4.30 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	152 894
Average Volume	253 857
Market Cap	317.01M
EPS	$-0.000640 ( 2024-05-16 )
Next earnings date	( $-0.640 ) 2024-06-11
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.10
ATR14	$0.0180 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-02	Ganot Ilan	Buy	1 553	Common Stock
2024-05-02	Ganot Ilan	Sell	462	Common Stock
2024-05-02	Ganot Ilan	Sell	1 553	Restricted Stock Units
2024-04-03	Smith Ian F	Buy	3 256	Common Stock
2024-04-03	Smith Ian F	Sell	3 256	Restricted Stock Units

INSIDER POWER
95.42
Last 96 transactions
Buy: 7 909 797 \| Sell: 209 632

Volume Correlation

Long: 0.06 (neutral)

Short: 0.24 (neutral)

Signal:(52.208) Neutral

Solid Biosciences Inc Correlation

10 Most Positive Correlations
GOODN	0.889
LEXX	0.881
FTCS	0.88
RTH	0.88
CELH	0.879
FEMY	0.865
AGNG	0.863
CHSCO	0.863
AIHS	0.858
SMCI	0.857

10 Most Negative Correlations
SABR	-0.837
AUR	-0.82
MYNA	-0.82
SSRM	-0.812
XEL	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Solid Biosciences Inc Correlation - Currency/Commodity

0.45
( neutral )

0.50
( neutral )

0.00
( neutral )

0.58
( weak )

0.00
( neutral )

-0.35
( neutral )

Solid Biosciences Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2023
Revenue:	$0
Gross Profit:	$-2.58M (0.00 %)
EPS:	$-4.83

FY	2022
Revenue:	$8.09M
Gross Profit:	$5.69M (70.25 %)
EPS:	$-7.70

FY	2021
Revenue:	$13.62M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-10.14

Financial Reports:

No articles found.

Solid Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Solid Biosciences Inc

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.